The new remedē EL-X model delivers extended longevity, reduced size, and an enhanced suite of diagnostics

ZOLL^® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the peer-reviewed journal Nature and Science of Sleep has published five-year results from the remedē System Post Approval Study.

ZOLL^® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has acquired Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).

Expanded insurance coverage now available in Pennsylvania, Delaware and West Virginia

Respicardia, Inc. announced today that Monument Health in Rapid City, South Dakota is the first center in the Dakotas to treat patients with the remedē^® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).